Eli Lilly case questions 1) Did Eli Lilly pursue the right strategy to enter the Indian market? It was a right strategy for Eli Lilly that started a joint venture with Ranbaxy to enter the Indian market. First of all, Ranbaxy was the second largest pharmaceutical company that manufactures bulk drugs and generic drugs in India, with a domestic market share of 15 per cent. It had established broad distribution network, and it was the second largest exporter of all products in India. Ranbaxy’s
Words: 496 - Pages: 2
Cymbalta Case Study Analysis Executive Summary Introduction: The Problem It’s April 2000 at Eli Lilly and Company where their flagship product Prozac is the leading brand of anti-depression medication and is set to expire in December 2003. Even though that is the official patent expiration date, no one within the company could be sure exactly how much time Prozac had left (Okef & Laufner, p.1). Patent expiration would mean that generic versions of the drug would flood the market and Prozac’s
Words: 695 - Pages: 3
Executive summary: With the fast approaching expiration of its Prozac patent, Eli Lilly has to decide regarding the future course of action of its next generation anti-depressant drug. In this case analysis, the company faces three critical decisions before NDA submission: 1) establish Cymbalta as efficacious for treating major depressive disorders (MDD) using once-a-day (QD) dosing, 2) pursue a separate pain indication in addition to submitting for an MDD using twice-daily (BID) dosing, and 3)
Words: 874 - Pages: 4
and Eli Lilly prepared to take a new erectile dysfunction medication to the market. Cialis would be positioned in a market which was currently dominated by Viagra, an erectile dysfunction medication that had been introduced by Pfizer in 1998. In the following case analysis, I will examine the process used by Lilly ICOS, LLC to bring Cialis to market. Utilizing the Harvard Business School Case “Product Team Cialis: Getting Ready to Market” I will point out certain facts surrounding the case, and
Words: 2108 - Pages: 9
MANAGEMENT OF TECHNOLOGY Case Brief on Eli Lilly: The Evista Project TIMELINE 4000-2000 BC – Ancient Egyptians developed compresses around Skull to stop migraines. 1876 – Eli Lilly founded in Indianapolis, Indiana by Colonel Eli Lilly. 1970s – Early research in Lilly on Serotonin. 1988 – Prozac launched to market 1991 – Serotonin “1f” receptor cloned by Lilly’s collaborator, Synaptic Pharmaceutical Corporation. CNS group starts screening serotonin like compounds from Lilly’s historical
Words: 1655 - Pages: 7
Abstract This report analyzes why Eli Lilly and Pfizer, both well-established companies, were unsuccessful in the introduction of innovative products, the 100 percent insulin “Humulin” and the first inhaled insulin “Exubera” and why “thinking big but acting small” is significant in the need to innovate and in knowing and keeping the customer. Big companies must think outside the box by solving their customer problems, making better products and creating value. Keywords: insulin, inhaler, customer
Words: 1221 - Pages: 5
Cymbalta case Analysis Mohamed A. Kamara AMBA 650: Marketing Management and Innovation January 22, 2013 Table of Contents 1.0. Identification of the strategic issues and problems. 2.0. Analysis and evaluation. 3.2. Recommendations. 1.0. Identification of the strategic issues and problems. In April 2000, Eli Lilly’s New Antidepressant Team (NAT) convenes to review the potentials of alternative medications, and to subsequently adopt a replacement to the company’s premier antidepressant
Words: 1238 - Pages: 5
Eli Lilly: The Evista Project® In early 1998 Dr. August “Gus” Watanabe, executive vice president of science and technology for Eli Lilly and president of Lilly Research Laboratories (see Exhibits 1 and 2), looked out his office window toward downtown Indianapolis. He was contemplating the future commercialization path for Lilly’s new, potential blockbuster drug, Evista®, which had received FDA approval on December 9, 1997, for the prevention of post-menopausal osteoporosis. Evista®
Words: 7202 - Pages: 29
CIALIS Case Analysis: Cialis Cialis is a prescription drug developed by the pharmaceutical company Lilly ICOS LLC, to treat Erectile Dysfunction (ED). The challenges include the need to launch Cialis on the market, where ED is an extremely sensitive topic of discussion and where there is already an established leader Viagra. Marketing Analysis Customers: Men who suffer from ED are targeted by Cialis. Especially the current unsatisfied Viagra users, Viagra dropouts and those who never used
Words: 839 - Pages: 4
BRAND MANAGEMENT AND DIGITAL MARKETING Product Team Cialis: Getting Ready to Market After creating a joint venture, Ely Lilly and ICOS (Lilly ICOS LLC) to develop and understand the target market for Cialis it is now time to decide if the product is good enough to be launched and if the answer is yes, with which strategy. The company has three approaches: follow a “niche” strategy, focusing in a specific segment; a “direct” strategy, going head-to-head against Viagra; or a “beat” strategy,
Words: 755 - Pages: 4
